Nebenwirkungen · Bosulif
Bosulif 100 mg film-coated tablets Bosulif 400 mg film-coated tablets Bosulif 500 mg film-coated tablets Bosulif 50 mg hard capsules Bosulif 100 mg hard capsules · Abschnitt 4.8 · PDF-Seite 16
HOS-125484 · Präparat HOS-096073
Blood and lymphatic system disorders Of the 372 (27.1%) adult patients with reports of adverse reactions of anaemia, 6 patients discontinued bosutinib due to anaemia. Maximum toxicity of Grade 1 occurred in 95 (25.5%) patients, Grade 2 in 135 (36.3%) patients, Grade 3 in 113 patients (30.4%), and Grade 4 in 29 (7.8%) patients. Among these patients, the median time to first event was 29 days (range: 1 to 3 999 days) and the median duration per event was 22 days (range: 1 to 3 682 days).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:15:00Z · SHA-256 86c38605c3386630b4591643bb4507bc13ee17f96b594c991ef48865ec55c6c0 · Passage a11f7c8bbe419fb522b8d57634384fc2efee8b418e1add9ea63c1e970f3a59ed · Zeichen 12511–13001 im Abschnitt